Reuters logo
BRIEF-Novartis receives FDA approval for first-of-its-kind kisqali femara co-pack for initial treatment of hr+/her2- advanced or metastatic breast cancer
May 8, 2017 / 9:02 PM / 7 months ago

BRIEF-Novartis receives FDA approval for first-of-its-kind kisqali femara co-pack for initial treatment of hr+/her2- advanced or metastatic breast cancer

May 8 (Reuters) - Novartis Ag

* Novartis receives FDA approval for first-of-its-kind Kisqali® Femara® co-pack for initial treatment of hr+/her2- advanced or Metastatic breast cancer Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below